title: Sickle cell disease pathophysiology.
abstract: The primary pathophysiological event in the erythrocytes of individuals with the various sickle syndromes is the intracellular aggregation or polymerization of sickle haemoglobin (HbS). The extent of polymerization is determined by the intracellular haemoglobin composition (% HbS and % HbS A, A2 and F), concentration (MCHC and % of dense cells) and oxygen saturation, as well as minor factors such as intracellular pH and DPG concentration. Intracellular HbS polymerization leads to a marked decrease in the flexibility or rheological properties of the sickle erythrocytes and obstruction in various microcirculatory beds, as well as chronic anaemia. Other abnormalities in the properties of the sickle erythrocytes, including membrane abnormalities, changes in ion fluxes and volume and endothelial adhesion, result from acute and chronic oxygen-linked polymerization events and may, in turn, modify polymerization. However, within a good approximation, many aspects of sickle cell disease pathophysiology--for example variations in anaemia among the different sickle syndromes--can be explained in terms of differences in polymerization tendency. Thus, the effects of alpha-thalassaemia can be explained with reference to changes in MCHC and syndromes with high HbF are understandable in terms of the sparing effect of HbF on polymerization. Recent therapeutic approaches to sickle cell disease focus on attempts to reduce intracellular HbS polymerization by altering the haemoglobin molecules, erythrocyte properties, or the distribution of intracellular haemoglobin species. The last, through pharmacological elevation of HbF, has become the central focus of much laboratory and clinical research in recent years. Agents such as hydroxyurea (with or without recombinant erythropoietin) and butyrate compounds elevate HbF (and reduce HbS) in a majority of sickle erythrocytes, thus decreasing intracellular polymerization. Current prospective protocols are designed to see if these changes cause clinical improvement at acceptable doses. Other treatment strategies, including bone marrow transplantation and possible gene replacement therapies, are also under active clinical or laboratory investigation.
authors.affiliation: Department of Health and Human Services, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: C T
authors.initials: CT
authors.lastname: Noguchi
authors.forename: A N
authors.initials: AN
authors.lastname: Schechter
authors.forename: G P
authors.initials: GP
authors.lastname: Rodgers
mesh_terms: D000755:Anemia, Sickle Cell / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D004910:Erythrocyte Membrane / Q000502:physiology; D004913:Erythrocytes, Abnormal / Q000502:physiology; D015316:Genetic Therapy; D006451:Hemoglobin, Sickle / Q000737:chemistry / Q000235:genetics; D006801:Humans; D012212:Rheology
chemical_list: D006451:Hemoglobin, Sickle